Company Overview of Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. discovers and develops novel antifungal agents through a proprietary medicinal chemistry platform. Its product includes VT-1161, an oral agent that is in Phase IIa clinical trials for the treatment of moderate to severe acute vulvovaginal candidiasis; and moderate to severe interdigital tinea pedis, a dermatologic infection. The company is also developing VT-1129, an oral agent for the treatment of cryptococcal meningitis, an invasive fungal infection of the lining of the brain and spinal cord; and VT-1598 and related analogues, which are in preclinical development to identify the optimal candidate to advance in development as an oral and intravenous therapy for ...
4505 Emperor Boulevard
Durham, NC 27703
Key Executives for Viamet Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Chief Business & Financial Officer
Chief Development Officer
Compensation as of Fiscal Year 2014.
Viamet Pharmaceuticals, Inc. Key Developments
Viamet Pharmaceuticals, Inc. Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis
Feb 12 15
Viamet Pharmaceuticals, Inc. announced the initiation of the REVIVE (REcurrent Vulvovaginal Candidiasis Inhibition; an Oral VT-1161 TabletÂ Evaluation) Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis (RVVC), a particularly refractory clinical condition. VT-1161 is a novel, orally-available, highly potent and selective inhibitor of fungal CYP51, a well validated antifungal target. As previously reported by Viamet, VT-1161 demonstrated robust antifungal activity and a favorable safety profile in a Phase 2a proof-of-concept study in the treatment of acute vulvovaginal candidiasis. REVIVE, which is a randomized, double-blind, placebo-controlled study, will enroll approximately 200 patients with a documented history of RVVC at approximately 25 clinical sites throughout the U.S. The study will evaluate two dose levels of VT-1161 administered once-weekly for either 11 or 23 weeks following an initial one-week loading-dose period. The primary endpoint for the study will be the prevention of acute episodes of vulvovaginal candidiasis through week 48 of the study, which extends either 24 or 36 weeks beyond the conclusion of dosing with VT-1161 depending on the dose group. An estimated 5-8% of women of child-bearing age suffer from recurring episodes of acute vulvovaginal candidiasis, a syndrome termed RVVC. There are currently no approved agents in the United States to prevent these recurring and difficult to treat infections. Current therapies, while effective for uncomplicated episodes of acute vulvovaginal candidiasis, are typically not effective in preventing recurrent infections. There is a significant unmet medical need for a safe and effective oral therapy to treat RVVC.
Viamet Pharmaceuticals, Inc. Presents at CED Life Science Conference 2015, Mar-03-2015 01:15 PM
Feb 11 15
Viamet Pharmaceuticals, Inc. Presents at CED Life Science Conference 2015, Mar-03-2015 01:15 PM. Venue: Raleigh Convention Center, Raleigh, North Carolina, United States. Speakers: Robert J. Schotzinger, Chief Executive Officer, President and Director.
Viamet Announces Appointment of Amir Tavakkol as Chief Development Officer
Jul 22 14
Viamet Pharmaceuticals, Inc. announced the appointment of Amir Tavakkol, Ph.D., as Chief Development Officer. Dr. Tavakkol brings over 25 years of experience in pharmaceuticals, consumer healthcare and academia, including substantial expertise in the clinical development of novel antifungal products for superficial as well as systemic indications. Dr. Tavakkol will have significant responsibility for the management of Viamet's clinical programs, including the ongoing clinical development of VT-1161, the Company's lead novel, oral antifungal compound. Prior to joining Viamet, Dr. Tavakkol most recently served as Senior Vice President of Clinical Development & Operations at Topica Pharmaceuticals Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|